Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 4Mesothelioma 4Solid Tumor 3Neoplasms 3Mesothelioma, Malignant 3Unspecified Adult Solid Tumor, Protocol Specific 2Small Cell Lung Carcinoma 2Advanced Solid Tumor 2Advanced Refractory Solid Tumors 2Uterine Cervical Neoplasms 1Solid Tumor, Childhood 1Psoriasis 1Prostatic Neoplasms 1Post-Lyme Disease Syndrome 1Parkinson Disease 1Obsessive-Compulsive Disorder 1Myasthenia Gravis 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis, Chronic Progressive 1Multiple Sclerosis 1Migraine Disorders 1Malignant Solid Neoplasm 1Lyme Neuroborreliosis 1Lyme Disease 1Lung Neoplasms 1Irritable Bowel Syndrome 1Hypercholesterolemia 1Hodgkin Disease 1Hematopoietic and Lymphoid System Neoplasm 1Hematopoietic and Lymphatic System Neoplasm 1

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Advance Solid Tumors × Other solid neoplasm × Clear all
NCT07529535 2026-04-17

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Zhejiang Anglikang Pharmaceutical Co., Ltd.

Phase 1 Suspended
16 enrolled
Other solid neoplasm

Advance Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡